ACROBiosystems Achieves Global Recognition with CiteAb Award for Protein Suppliers in Cancer Research

ACROBiosystems Wins Cited Honor in Cancer Research

ACROBiosystems, a forward-thinking biotechnology firm based in San Diego and Newark, recently made headlines by receiving the prestigious title of "Protein Supplier to Watch in Cancer Research in 2026" at the CiteAb Awards. This recognition signifies a notable achievement not only for the company but also for its role in advancing the field of cancer research.

The CiteAb platform serves as an influential entity in the scientific community, offering a vast database that catalogs various suppliers and their products. The awards presented by CiteAb leverage high-quality citation data from scientific publications, which allows for an impartial assessment of excellence. ACROBiosystems emerged prominently among over 300 suppliers, securing a commendable second place in year-over-year growth of protein citations related to cancer studies.

At the American Association for Cancer Research (AACR) event, the award was presented to Dr. Yu Sun, the Vice President of Product Development at ACROBiosystems. During the award ceremony, Dr. Sun expressed his gratitude, stating, “I am truly delighted that our proteins have earned top citations from scientists—this represents recognition and trust from the industry.” His enthusiasm underscored the company's commitment to providing high-quality products that are integral to groundbreaking research.

ACROBiosystems' extensive portfolio offers more than just proteins; it also includes antibodies, research kits, and various services that cater to a wide range of therapeutic areas, from oncology to autoimmune conditions, cardiovascular issues, infectious diseases, and neurology. Their products are designed to support key processes from research and development (R&D) to production methodologies, including drug screening, preclinical trials, and clinical applications.

One of the defining aspects of ACROBiosystems is its unwavering commitment to quality and innovation, encapsulated by its brand values of 'Reliable Quality, Integrated Innovation, Considerate Service.' The company's strategic efforts were solidified with its ISO 9001 certification in 2016 and the establishment of a Good Manufacturing Practice (GMP) system in 2021, leading up to dual certification of ISO 9001 and GMP at its Suzhou production site in 2024. This rigorous quality management framework allows ACROBiosystems to stay compliant with global regulations and adapt quickly to market needs.

In addition to quality, ACROBiosystems places a significant focus on customer service, offering efficient logistics for prompt deliveries, round-the-clock technical support, a repository of resources to assist users, and customized attention through dedicated service teams. The company recognizes that exceptional service is crucial to fostering long-term relationships with partners and clients.

Moreover, ACROBiosystems embodies 'Integrated Innovation' by aligning with emerging therapeutic modalities and actively engaging in collaborations across global innovation ecosystems. Their use of advanced technology platforms enhanced by artificial intelligence (AI) positions them to be leaders in the ever-evolving biopharmaceutical landscape.

Founded in 2010 and publicly listed in 2021, ACROBiosystems has cemented its presence in the global biotechnology arena. With research and development centers, production facilities, and offices scattered across more than 15 cities worldwide, they maintain stable partnerships with numerous pharmaceutical giants such as Pfizer, Novartis, and Johnson & Johnson, alongside various esteemed academic institutions. The company comprises several subsidiaries, including ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics, each contributing to the company's overarching mission—to accelerate drug development, particularly in targeted therapies and immunotherapeutic drugs.

In conclusion, ACROBiosystems stands at the forefront of innovation in the biopharmaceutical sector, continuously evolving to meet the challenges of today’s healthcare demands. As they receive recognition through awards like the CiteAb, their contributions mark significant strides towards enhancing global health outcomes, reaffirming their mantra of powering discoveries and breakthroughs for a healthier tomorrow.